Annotation Detail

Information
Associated Genes
BRAF
Associated Variants
BRAF MUTATION
BRAF MUTATION
Associated Disease
Solid Tumor
Source Database
CIViC Evidence
Description
In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligible and received therapy with trametinib. Most common tumor histopathologic subtypes were GI cancers (n=8, of which 7 were colorectal adenocarcinoma), lung adenocarcinoma (n=9), prostate adenocarcinoma (n=4), gynecologic cancer (n=4), BRAF alterations included BRAF fusion (n=1), G464 (n=2), G466 (n=4), G469 (n=7), N581 (n=3), D594 (n=11), L597 (n=2) and K601 (n=1). Of the 32 patients evaluable for efficacy endpoints, the response rate was 3% (3/32). The patient with a partial response had invasive breast cancer with a BRAF G469E mutation. The median PFS was 1.8 months and the median OS was 5.7 months.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7855
Gene URL
https://civic.genome.wustl.edu/links/genes/5
Variant URL
https://civic.genome.wustl.edu/links/variants/2408
Rating
4
Evidence Type
Predictive
Disease
Solid Tumor
Evidence Direction
Does Not Support
Drug
Trametinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
31924734
Drugs
Drug NameSensitivitySupported
TrametinibSensitivityfalse